The Russian biopharmaceutical company Petrovax has reached an agreement with the Chinese company Jiangsu Hengrui for the supply of drugs, including the oncological drug camrelizumab. It is planned to register it in the Russian Federation in 2024 with further localization of the drug in the country up to the substance phase, Kommersant reported.
Camrelizumab belongs to the PD-1 protein inhibitors, the same class as pembrolizumab (MSD’s original drug Keytruda) and nivolumab (Opdivo from the US company BMS).
According to Headway Company, pembrolizumab and nivolumab lead government procurement in the oncology drugs segment in January-September 2023. During this time, public procurement operators purchased a total of 26.5 billion rubles from these funds.
Camrelizumab was approved three years ago in China to treat liver cancer. The drug is being tested for other indications. The US Food and Drug Administration (FDA) is currently reviewing an application from Jiangsu Hengrui and its South Korean partner to register this drug in combination with another drug.
After February 2022, international pharmaceutical companies, including Pfizer, Eli Lilly, Novartis, Viatris, Sanofi, MSD, suspended investments in Russia, as well as new clinical trials.
Author:
Karina Pardaeva
Source: RB
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
